In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap | GenomeWeb

By Julia Karow and Bernadette Toner

Sixty percent of next-generation sequencing users recently polled by In Sequence operate an Illumina sequencer, while only a third own a 454 or a SOLiD platform, confirming Illumina's dominant position in the marketplace.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.